- Home
- AKBA vs UFCS Comparison
AKBA vs UFCS Comparison
Compare AKBA & UFCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- UFCS
- Stock Information
- Founded
- AKBA 2007
- UFCS 1946
- Country
- AKBA United States
- UFCS United States
- Employees
- AKBA N/A
- UFCS 877
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- UFCS Property-Casualty Insurers
- Sector
- AKBA Health Care
- UFCS Finance
- Exchange
- AKBA Nasdaq
- UFCS Nasdaq
- Market Cap
- AKBA 861.7M
- UFCS 791.8M
- IPO Year
- AKBA 2014
- UFCS N/A
- Fundamental
- Price
- AKBA $2.95
- UFCS $31.70
- Analyst Decision
- AKBA Strong Buy
- UFCS Buy
- Analyst Count
- AKBA 5
- UFCS 2
- Target Price
- AKBA $6.90
- UFCS $30.50
- AVG Volume (30 Days)
- AKBA 3.9M
- UFCS 118.3K
- Earning Date
- AKBA 11-06-2025
- UFCS 11-04-2025
- Dividend Yield
- AKBA N/A
- UFCS 2.01%
- EPS Growth
- AKBA N/A
- UFCS 143.32
- EPS
- AKBA N/A
- UFCS 3.51
- Revenue
- AKBA $203,733,000.00
- UFCS $1,322,727,000.00
- Revenue This Year
- AKBA $38.23
- UFCS $12.34
- Revenue Next Year
- AKBA $38.17
- UFCS $14.56
- P/E Ratio
- AKBA N/A
- UFCS $9.10
- Revenue Growth
- AKBA 16.75
- UFCS 14.18
- 52 Week Low
- AKBA $1.24
- UFCS $19.19
- 52 Week High
- AKBA $4.08
- UFCS $32.13
- Technical
- Relative Strength Index (RSI)
- AKBA 40.51
- UFCS 61.17
- Support Level
- AKBA $2.92
- UFCS $30.53
- Resistance Level
- AKBA $3.15
- UFCS $31.97
- Average True Range (ATR)
- AKBA 0.14
- UFCS 0.66
- MACD
- AKBA 0.01
- UFCS -0.04
- Stochastic Oscillator
- AKBA 18.75
- UFCS 73.85
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.